BofA lowered the firm’s price target on Buenaventura (BVN) to $12 from $14 and keeps a Neutral rating on the shares. The company’s Q1 results were largely uneventful with a reiteration of R&D program timelines, and the firm maintains its view that shares could be range-bound until the company can address its financing overhang amidst 2026 catalysts, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVN:
- Buenaventura Earnings Call Signals Profitable Growth Ahead
- Buenaventura Files 2025 Form 20-F Annual Report with U.S. SEC
- Buenaventura Reshapes Board Leadership With New Chairman and Lead Director
- Buenaventura Posts Surging Q1 2026 Profit as San Gabriel Ramps Up and Cash Position Strengthens
- Buenaventura reports Q1 EPS $1.32, two estimates $1.15